Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis - 16/07/18
, Yevgeniy Balagula, MD c, d, Joseph F. Merola, MD, MMSc eAbstract |
In addition to being recognized as a chronic inflammatory disease that manifests in the skin, psoriasis is increasingly understood to be a systemic disease that causes immune dysregulation throughout the body. The systemic nature of psoriasis is evidenced by the higher burden of comorbidities and shorter life expectancies of patients with psoriasis, particularly those with early-onset and severe disease. Notably, psoriasis is associated with an increased risk for cardiovascular disease, which is the most common cause of morbidity and mortality in patients with psoriasis. In this review, we examine the association between psoriasis and cardiovascular disease and specifically focus on the role of interleukin 17–mediated inflammation as a potential mechanistic link between psoriasis and cardiovascular disease. Moreover, we describe potential treatment approaches to reduce the burden of cardiovascular disease in patients with psoriasis and discuss the clinical importance of the association of these 2 diseases with respect to patient management and education.
Il testo completo di questo articolo è disponibile in PDF.Key words : anti-inflammatory therapy, cardiovascular disease, comorbidities, IL-17, interleukin 17, psoriasis, systemic inflammation
Abbreviations used : CV, CVD, FDG-PET/CT, IFN-γ, IL, MI, PY, Th17, TNF-α
Mappa
| Funding sources: Technical assistance with editing, figure preparation, and styling of the manuscript for submission was provided by Oxford PharmaGenesis, Inc, and funded by Novartis Pharmaceuticals Corporation. |
|
| Disclosure: Dr Lockshin has served as an investigator for Novartis, Eli Lilly, AbbVie, Leo Pharma, Janssen, and Amgen; consulted for Janssen and AbbVie; and served as a speaker for Novartis, Janssen, Eli Lilly, and AbbVie. Dr Merola is a consultant and/or investigator for Biogen IDEC, Amgen, AbbVie, Eli Lilly, Novartis, Pfizer, Janssen, UCB, Kiniksa, Momenta, and Mallinckrodt; has received a grant from Biogen IDEC; and has licensed a questionnaire to AbbVie and Eli Lilly. Dr Balagula has no conflicts of interest to disclose. |
|
| The authors are fully responsible for all content and editorial decisions and have received no financial support or other form of compensation related to the development of this manuscript. |
|
| Reprints not available from the authors. |
Vol 79 - N° 2
P. 345-352 - agosto 2018 Ritorno al numero
Articolo precedente
- A 10-point plan to demonstrate the value of dermatology in the health care system
- Henry W. Lim, Karen E. Edison, Krista D. Kauper, Melanie Tolley Hall, Missy Lundberg, Katie Domanowski
- Biologics for pityriasis rubra pilaris treatment: A review of the literature
- Monica Napolitano, Damiano Abeni, Biagio Didona
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?